Dr. Michael I. Ghilezan, MD, PhD

Dr. Ghilezan practices at Mhp Radiation Oncology Institute in Farmington Hills, Michigan.

Dr. Ghilezan's NPI, 1164481859, was assigned on March 21, 2006. Dr. Ghilezan graduated from Iuliu Hatieganu University of Medicine and Pharmacy in 1988. Dr. Ghilezan holds Michigan license 4301079938.

Dr. Ghilezan's primary practice is Mhp Radiation Oncology Institute, at 30000 Northwestern Hwy, Farmington Hills, MI 48334 in Oakland County. The practice phone is (248) 589-5000.

Dr. Ghilezan's primary practice is Mhp Radiation Oncology Institute in Farmington Hills, Michigan. Dr. Ghilezan is also affiliated with Corewell Health Farmington Hills Hospital. The medical group on file is MHP Radiation Oncology Institute. Dmand AI also links Dr. Ghilezan to 3 more hospitals, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ghilezan practices, 8 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Ghilezan's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Ghilezan is board certified in radiation oncology by the American Board of Radiology. Dr. Ghilezan is licensed in Michigan.

Dmand AI lists bladder cancer radiation, breast cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Ghilezan treats.

CMS data shows 5,793 Medicare services from Dr. Ghilezan across 19 procedure codes in 2024, for 196 Medicare patients. Medicare paid $899,213 for them. Every service was in an office.

CMS counts 196 Medicare patients who saw Dr. Ghilezan in 2024. The largest group is 65 to 74, with 94 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ghilezan's median patient age at 72, with 4% women.

In 2024, Dr. Ghilezan wrote 308 Medicare Part D claims for 123 patients. 98% of them were for generic drugs. CMS names the drug for 260 of them, across 3 drugs with 11 or more claims each, at $3,240 in total drug cost. In 2023, CMS named 227 claims across 3 drugs.

Dr. Ghilezan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ghilezan as offering telehealth.

Dmand AI links 2 papers to Dr. Ghilezan, published from 2017 to 2022. Dr. Ghilezan's most frequent co-authors are Savitha Balaraman, MD, Gary S. Gustafson, MD and Andrew Stephen Korman, MD.

Dmand AI links Dr. Ghilezan to 1 clinical trial. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 28 general payments to Dr. Ghilezan from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Augmenix, Inc. paid the most, $214.

Dmand AI lists 1 award for Dr. Ghilezan, most recently CMS Stage 1 EHR in 2013.

Dr. Ghilezan graduated from Iuliu Hatieganu University of Medicine and Pharmacy in 1988.

Dr. Ghilezan is in network with 18 carriers, including Aetna, Elevance and Health Alliance Plan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.